Navigation Links
Study Shows Positron Emission Mammography (PEM) is Easy for Breast Imagers to Learn Regardless of Experience
Date:4/6/2011

SAN DIEGO, April 6, 2011 /PRNewswire/ -- The American Journal of Roentgenology published original research from two separate studies this month demonstrating continued clinical acceptance of  the Naviscan high-resolution breast PET scanner, otherwise known as a PEM scanner.  The first study concluded that breast radiologists can achieve a high level of diagnostic performance in interpreting PEM images after a 2-hour tutorial which can take months to achieve with MRI.  The second study established a standard lexicon for the evaluation of PEM images making it simple to share a diagnosis.

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment.  With increasing use of PEM imaging, there is a need for standardized terminology to describe findings seen on PEM, interpretation, and management recommendations, similar to the standardized classification that exists for other breast imaging modalities.  

The purpose of the interpretative skills study was to prospectively validate how easy it is to learn and standardize the interpretation of PEM by breast radiologists.  Thirty-six observers from 15 sites throughout the United States completed both PEM and MRI interpretive skills tasks.  All participants underwent a 2-hour training program for interpreting PEM images.  The median sensitivity and specificity for PEM assessment tasks were 100% and 83% respectively, compared to the median sensitively and specificity of MRI at 82% and 69% respectively. The results indicate that, with minimal training, experienced breast imagers showed high performance in interpreting PEM images.

"PEM interpretation is relatively simple," stated Dr. Priscilla Slanetz, Director of Breast Imaging Research and Education at Beth Israel Deaconess Medical Center, a participant in the study.  "Assessing for areas of focal uptake typically is straightforward and takes just 1-3 minutes at most. In comparison, interpreting breast MR can take anywhere between 5-20 minutes, depending upon the complexity of the case and the number of sequences acquired."

Complementing this study, the lexicon paper outlines a standardized terminology to report PEM findings, similar to the BI-RADS developed through the American College of Radiology used extensively for mammography, ultrasound, and breast MRI.  Twenty investigators reviewed 404 malignancies in 388 patients in the development of the PEM lexicon.  The most interesting finding was that category 3, "probably benign," had a substantially higher rate of malignancy when compared to other modalities demonstrating how PEM is more accurate and decisive at differentiating between malignant and benign lesions in what is called "specificity."  Ultimately, PEM's high specificity has been suggested to be able to reduce unnecessary biopsies.  

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
(Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
(Date:6/23/2016)... SAN DIEGO , June 23, 2016 /PRNewswire/ ... advancing programs that address medical conditions resulting from ... that it has appointed Greg Doyle ... member of Leading BioSciences, executive management team and ... officer and chief financial officer. He will provide ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
Breaking Medicine News(10 mins):